Cell No. : Cell Name
RCB1907 : TKKK
update : 2021/02/26
|
| Comment | Human cell line derived from intrahepatic bile duct cancer. TKG0456 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Obinata, Masuo
|
| Originator |
Katayose, Y.
|
| Year of deposit |
2004
|
| Original cell |
TKG0456
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Tissue |
Intrahepatic bile duct
|
| Disease name |
intraohepatic bile duct carcinoma
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0456）
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
(0.05% trypsin + 0.02% EDTA) or (0.25% trypsin + 0.02% EDTA)
|
| Coating dish |
|
type I collagen coated dish
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/4 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| STR(human) |
|
OK
|
| Virus (HBV) |
|
(-)
|
| Virus (HCV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
15
|
| User's Publication |
|
3737
Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Cells
2019
8(9):1026
PubMed ID: 31484399
|
|
10759
Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Jpn. J. Clin. Oncol.
2018
48:396-399
PubMed ID: 29474549
|
|
10290
Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Mol. Carcinog.
2017
56:2146-2157
PubMed ID: 28467612
|
|
3727
Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Mol Oncol
2017
11(9):1130-1142
PubMed ID: 28544747
|
|
3735
Saha SK et al
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov
2016
6(7):727-39
PubMed ID: 27231123
|
|
7256
Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R, Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H, Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y, Masaki T.
Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
Int. J. Oncol.
2015
47:1293-302
PubMed ID: 26252371
|
|
3736
Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.
Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.
Mol Cancer Ther.
2015
14(9):1985-93
PubMed ID: 26141945
|
|
12541
Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.
ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma
Hepatol Res
2014
44(14):E320-34
PubMed ID: 24552196
|
|
13689
Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T.
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma
Jpn J Clin Oncol
2014
44(6):570-8
PubMed ID: 24755544
|
|
3722
Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.
Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
Cancer Sci
2012
103(2):252-61
PubMed ID: 22044563
|
|
7767
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
Br. J. Cancer
2011
105:131-8
PubMed ID: 21673683
|
|
7862
Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J Hepatobiliary Pancreat Sci
2011
18:700-11
PubMed ID: 21451941
|
|
13667
Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment
Cancer Sci
2010
101(4):882-8
PubMed ID: 20088962
|
|
3705
Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y.
Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer.
World J Gastroenterol
2009
15(31):3865-73
PubMed ID: 19701966
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
|
Back
Top
CELL BANK Website
